Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics)
26. April 2024 09:42 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Liver Cirrhosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics)
11. April 2024 11:06 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Cirrhosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight
25. März 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...
2021 Pipeline Analysis for Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis: Therapeutic Assessment, Unmet Needs and Impact of Drugs
04. Mai 2021 04:03 ET
|
Research and Markets
Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "Advanced Hepatocellular Carcinoma with CPB liver cirrhosis - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering....